C

Cambridge Medical Trials | Alexandria, LA

Research site
(Unclaimed)
Location
501 Medical Center Drive, Suite 250, Alexandria, Louisiana, United States of America
Site insights

Top conditions

Atrial Fibrillation (6 trials)

Cardiovascular Diseases (4 trials)

Atherosclerosis (4 trials)

Heart Failure (3 trials)

Respiratory Tract Infections (2 trials)

Top treatments

Apixaban
Obicetrapib
EMPagliflozin
Pemafibrate
Milvexian
Semaglutide
CPI-006
Triglycerides
Ziltivekimab
sodium

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

8 of 20
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Other: Placebo
Drug: Milvexian

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo
Locations recently updated

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHFTM pl...

Enrolling
Heart Failure
Device: BiovitalsHF

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Enrolling
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Obicetrapib

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholester...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Dyslipidemias
Drug: Obicetrapib
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Boehringer Ingelheim logo

Boehringer Ingelheim (2 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems